Opendata, web and dolomites

Syn2Psy SIGNED

Synaptic Dysfunction in Neuropsychiatric Disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Syn2Psy project word cloud

Explore the words cloud of the Syn2Psy project. It provides you a very rough idea of what is the project "Syn2Psy" about.

acquired    therapeutic    skills    abnormal    biological    employment    plasticity    university    mental    connectivity    functional    child    neuropsychiatric    clinic    neuroimaging    training    synaptic    complementary    transferable    public    regulate    combines    drive    patients    inform    health    alleviating    disorders    esrs    therapies    14    careers    animal    illness    ph    answer    aetiology    diverse    time    genetic    neuronal    academic    basis    circuits    critical    hospital    area    coimbra    human    identification    soft    worldwide    drug    company    train    scientific    network    underpinning    thriving    prospects    actions    eurotrials    burden    contributions    individual    flourishing    stage    lundbeck    zeiss    speaks    signatures    convergent    integrate    risk    basic    course    industrial    clinical    questions    modulate    theatre    defects    disease    structural    suffering    expose    disrupted    generation    students    models    brain    excellent    marionet    pin    synapse    implicated    sectors    trials    outreach    societal    disability    syn2psy    levels   

Project "Syn2Psy" data sheet

The following table provides information about the project.

Coordinator
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO 

Organization address
address: UNIVERSIDADE DE COIMBRA, LARGO DE POMBAL
city: COIMBRA
postcode: 3004 517
website: www.cnbc.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 3˙885˙134 €
 EC max contribution 3˙885˙134 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2023-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO PT (COIMBRA) coordinator 713˙160.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 1˙099˙208.00
3    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 606˙345.00
4    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 606˙345.00
5    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 562˙553.00
6    H. LUNDBECK AS DK (VALBY) participant 297˙522.00
7    CARL ZEISS SMS GMBH DE (JENA) partner 0.00
8    CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E. PT (COIMBRA) partner 0.00
9    Eurotrials Scientific Consultants PT (Lisboa) partner 0.00
10    MARIONET-ASSOCIACAO CULTURAL PT (COIMBRA) partner 0.00
11    PIN - Progresso Infantil PT (Paço de Arcos) partner 0.00

Map

 Project objective

The large public health burden and individual suffering associated with mental disorders speaks to the need to study their biological underpinning. Genetic research, animal models of disease and human neuroimaging studies have provided convergent evidence to common pathways implicated in their aetiology, namely pathways that regulate synapse development and plasticity, which result in abnormal structural and functional connectivity in the brain of neuropsychiatric patients. The time has come to integrate studies across different levels, leading to the identification of signatures of illness associated to specific risk pathways, which can drive the development of novel therapies.

The objective of Syn2Psy is to provide high-level Ph.D. training for 14 early stage researchers (ESRs) to answer three critical questions: 1) What are the synaptic defects at the basis of neuropsychiatric disorders? 2) Which are the neuronal circuits that are disrupted, and may be targets for therapies? 3) How and when can we modulate the course of disease? Syn2Psy combines strong scientific with complementary know-how from the non-academic sector, and network-wide actions on scientific and complementary soft skills, to train a new generation of high achieving ESRs and provide them with the transferable skills necessary for thriving careers in a flourishing area. Industrial partners Lundbeck, Eurotrials and ZEISS provide experience on drug, clinical trials and technology development, the Coimbra University Hospital will expose the students to clinical research, while the clinic for child development PIN and the Marionet theatre company offer training in societal awareness and outreach. The excellent basic scientific knowledge and diverse skills acquired by ESRs will enhance their employment prospects in both the academic and non-academic sectors, and their scientific contributions will inform novel therapeutic approaches for alleviating this leading cause of disability worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN2PSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYN2PSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

FutureArctic (2019)

A glimpse into the Arctic future: equipping a unique natural experiment for next-generation ecosystem research

Read More  

LongActNow (2019)

Long Acting Medicines for Complex Therapeutics Needed Now

Read More